Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-CARMSLN-NK
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-CARMSLN-NK is an allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting mesothelin (MSLN). Developed by Beijing Biotech (Biotech Pharmaceutical), it is being evaluated in a Phase 1/2 clinical trial for the treatment of relapsed or refractory B2 thymoma and thymic carcinoma. The therapy involves engineering NK cells to express a CAR specific to mesothelin, a cell surface glycoprotein often overexpressed in various solid tumors, including thymic malignancies. This allogeneic "off-the-shelf" approach aims to provide a more accessible and potentially safer alternative to autologous CAR-T cell therapies by utilizing donor-derived NK cells that are less likely to cause graft-versus-host disease or severe cytokine release syndrome.
- Other names
- mesothelin-CAR-NKMSLN-CAR-NK
02
Targets
Mesothelin
Beyond the preview
Go deeper on EB-CARMSLN-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-CARMSLN-NK.